BiotechTube
Home/Ability Biotherapeutics/Angèle Maki, Ph.D.
AM

Angèle Maki, Ph.D.

Chief Business Officer

Ability Biotherapeutics

Therapeutic Areas

OncologyImmunology

Ability Biotherapeutics Pipeline

DrugIndicationPhase
Leap 1121Autoimmune diseasePreclinical
Leap 1009Immuno‑oncology / Solid tumorsPreclinical
Leap 1030Immuno‑oncology / Solid tumorsPreclinical
Undisclosed programAutoimmune & Immuno‑oncologyPreclinical

Leadership Team at Ability Biotherapeutics

GD
Giles Day, M.Sc.
Chief Executive Officer
JB
Jean‑Philippe Bürckert, M.Sc., Ph.D.
Chief Technology Officer
PG
Patricia Giblin, Ph.D.
Chief Science Officer
View full Ability Biotherapeutics profile